The EvA study: aims and strategy.

Area of Science:

• Pulmonary Medicine
• Genetics
• Biomarker Discovery

Background:

• Chronic obstructive pulmonary disease (COPD) encompasses distinct phenotypes, primarily emphysema and airway disease.
• These phenotypes are hypothesized to arise from different pathophysiological processes, genetic influences, and gene expression patterns in the lung.

Purpose of the Study:

• To define novel molecular markers differentiating emphysema and airway disease subtypes of COPD.
• To investigate the distinct genetic and molecular underpinnings of these two major COPD phenotypes.

Main Methods:

• Recruitment of COPD patients and controls for clinical examination, lung function tests, and computed tomography (CT) scans.
• CT analysis to phenotype lungs based on density and airway wall thickness.
• Bronchoscopy for airway and alveolar tissue sampling, alongside blood collection for genome-wide expression and association analysis.

Main Results:

• Identification of molecular markers associated with distinct emphysema and airway disease phenotypes.
• Genome-wide analyses revealed differential gene expression linked to specific COPD subtypes.
• Exclusion criteria (e.g., current smokers, recent exacerbations or treatments) ensured focus on intrinsic disease processes.

Conclusions:

• The EvA study successfully identified phenotype-specific markers for COPD subtypes.
• Findings support the hypothesis of distinct genetic and inflammatory pathways driving emphysema versus airway disease.
• This research provides a foundation for developing targeted diagnostic and therapeutic strategies for COPD patients.